IPCA Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic t… Read more
IPCA Laboratories Limited (IPCALAB) - Net Assets
Latest net assets as of September 2025: ₹88.66 Billion INR
Based on the latest financial reports, IPCA Laboratories Limited (IPCALAB) has net assets worth ₹88.66 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹122.63 Billion) and total liabilities (₹33.97 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹88.66 Billion |
| % of Total Assets | 72.3% |
| Annual Growth Rate | 17.63% |
| 5-Year Change | 77.86% |
| 10-Year Change | 271.3% |
| Growth Volatility | 9.22 |
IPCA Laboratories Limited - Net Assets Trend (2005–2025)
This chart illustrates how IPCA Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IPCA Laboratories Limited (2005–2025)
The table below shows the annual net assets of IPCA Laboratories Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹83.88 Billion | +8.56% |
| 2024-03-31 | ₹77.27 Billion | +30.63% |
| 2023-03-31 | ₹59.15 Billion | +6.74% |
| 2022-03-31 | ₹55.42 Billion | +17.51% |
| 2021-03-31 | ₹47.16 Billion | +29.53% |
| 2020-03-31 | ₹36.41 Billion | +16.04% |
| 2019-03-31 | ₹31.38 Billion | +16.71% |
| 2018-03-31 | ₹26.89 Billion | +9.50% |
| 2017-03-31 | ₹24.55 Billion | +8.68% |
| 2016-03-31 | ₹22.59 Billion | +2.30% |
| 2015-03-31 | ₹22.08 Billion | +12.69% |
| 2014-03-31 | ₹19.60 Billion | +26.12% |
| 2013-03-31 | ₹15.54 Billion | +23.90% |
| 2012-03-31 | ₹12.54 Billion | +19.32% |
| 2011-03-31 | ₹10.51 Billion | +21.59% |
| 2010-03-31 | ₹8.64 Billion | +36.99% |
| 2009-03-31 | ₹6.31 Billion | +7.08% |
| 2008-03-31 | ₹5.89 Billion | +24.37% |
| 2007-03-31 | ₹4.74 Billion | +27.88% |
| 2006-03-31 | ₹3.70 Billion | +13.64% |
| 2005-03-31 | ₹3.26 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to IPCA Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11193.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹55.31 Billion | 79.61% |
| Common Stock | ₹253.70 Million | 0.37% |
| Other Components | ₹13.92 Billion | 20.03% |
| Total Equity | ₹69.48 Billion | 100.00% |
IPCA Laboratories Limited Competitors by Market Cap
The table below lists competitors of IPCA Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Envestnet Inc
NYSE:ENV
|
$2.68 Billion |
|
Weihai Guangwei Composites Co Ltd
SHE:300699
|
$2.68 Billion |
|
Jumbo S.A.
AT:BELA
|
$2.68 Billion |
|
Infrastrutture Wireless Italiane S.p.A
PINK:IFSUF
|
$2.68 Billion |
|
Vodacom Group Ltd PK
PINK:VDMCY
|
$2.68 Billion |
|
Rubis SCA
PA:RUI
|
$2.68 Billion |
|
FDJ United
LSE:0A8B
|
$2.68 Billion |
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
$2.68 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IPCA Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 63,321,900,000 to 69,484,500,000, a change of 6,162,600,000 (9.7%).
- Net income of 7,376,800,000 contributed positively to equity growth.
- Dividend payments of 1,014,800,000 reduced retained earnings.
- Other comprehensive income increased equity by 999,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹7.38 Billion | +10.62% |
| Dividends Paid | ₹1.01 Billion | -1.46% |
| Other Comprehensive Income | ₹1000.00K | +0.0% |
| Other Changes | ₹-200.40 Million | -0.29% |
| Total Change | ₹- | 9.73% |
Book Value vs Market Value Analysis
This analysis compares IPCA Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.72x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 120.03x to 5.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹13.04 | ₹1565.30 | x |
| 2006-03-31 | ₹14.82 | ₹1565.30 | x |
| 2007-03-31 | ₹18.89 | ₹1565.30 | x |
| 2008-03-31 | ₹23.47 | ₹1565.30 | x |
| 2009-03-31 | ₹25.06 | ₹1565.30 | x |
| 2010-03-31 | ₹34.55 | ₹1565.30 | x |
| 2011-03-31 | ₹41.91 | ₹1565.30 | x |
| 2012-03-31 | ₹49.74 | ₹1565.30 | x |
| 2013-03-31 | ₹61.58 | ₹1565.30 | x |
| 2014-03-31 | ₹77.64 | ₹1565.30 | x |
| 2015-03-31 | ₹87.50 | ₹1565.30 | x |
| 2016-03-31 | ₹89.51 | ₹1565.30 | x |
| 2017-03-31 | ₹97.28 | ₹1565.30 | x |
| 2018-03-31 | ₹106.51 | ₹1565.30 | x |
| 2019-03-31 | ₹123.58 | ₹1565.30 | x |
| 2020-03-31 | ₹143.44 | ₹1565.30 | x |
| 2021-03-31 | ₹185.63 | ₹1565.30 | x |
| 2022-03-31 | ₹216.47 | ₹1565.30 | x |
| 2023-03-31 | ₹230.27 | ₹1565.30 | x |
| 2024-03-31 | ₹249.59 | ₹1565.30 | x |
| 2025-03-31 | ₹273.88 | ₹1565.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IPCA Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.62%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.25%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 1.69x
- Recent ROE (10.62%) is below the historical average (16.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 22.72% | 10.91% | 0.99x | 2.11x | ₹414.83 Million |
| 2006 | 16.60% | 8.10% | 1.03x | 1.99x | ₹244.50 Million |
| 2007 | 26.63% | 13.44% | 1.04x | 1.91x | ₹787.91 Million |
| 2008 | 23.07% | 12.93% | 0.91x | 1.97x | ₹770.06 Million |
| 2009 | 15.97% | 7.85% | 0.94x | 2.17x | ₹376.68 Million |
| 2010 | 23.74% | 13.17% | 0.97x | 1.87x | ₹1.19 Billion |
| 2011 | 24.99% | 13.83% | 0.99x | 1.82x | ₹1.58 Billion |
| 2012 | 22.03% | 11.71% | 1.01x | 1.86x | ₹1.51 Billion |
| 2013 | 20.82% | 11.50% | 1.04x | 1.74x | ₹1.68 Billion |
| 2014 | 24.42% | 14.58% | 1.02x | 1.64x | ₹2.83 Billion |
| 2015 | 11.51% | 8.09% | 0.82x | 1.73x | ₹333.87 Million |
| 2016 | 4.12% | 3.25% | 0.74x | 1.72x | ₹-1.33 Billion |
| 2017 | 7.92% | 6.16% | 0.80x | 1.61x | ₹-509.86 Million |
| 2018 | 8.91% | 7.29% | 0.80x | 1.53x | ₹-294.37 Million |
| 2019 | 14.25% | 11.78% | 0.83x | 1.46x | ₹1.33 Billion |
| 2020 | 16.71% | 13.04% | 0.88x | 1.45x | ₹2.44 Billion |
| 2021 | 24.25% | 21.03% | 0.89x | 1.29x | ₹6.70 Billion |
| 2022 | 16.10% | 15.16% | 0.76x | 1.39x | ₹3.35 Billion |
| 2023 | 8.07% | 7.54% | 0.72x | 1.48x | ₹-1.13 Billion |
| 2024 | 8.64% | 7.10% | 0.69x | 1.75x | ₹-858.69 Million |
| 2025 | 10.62% | 8.25% | 0.76x | 1.69x | ₹428.35 Million |
Industry Comparison
This section compares IPCA Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IPCA Laboratories Limited (IPCALAB) | ₹88.66 Billion | 22.72% | 0.38x | $2.68 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |